New Zealand In Vitro Diagnostics Market Outlook to 2018

							New Zealand In Vitro Diagnostics Market Outlook to
2018
GlobalData’s new report, “New Zealand In Vitro Diagnostics Market Outlook to 2018 - Clinical
Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry,
Infectious Immunology and Microbiology Culture” provides key market data on the New
Zealand In Vitro Diagnostics market. The report provides value (USD million) data for each
segment and sub-segment within market categories – Clinical Chemistry, Haematology,
Immuno Chemistry, Histology And Cytology, Infectious Immunology, Microbiology Culture and
Genetic Testing. The report also provides company shares and distribution shares data for each
of the aforementioned market categories. The report is supplemented with global corporate-
level profiles of the key market participants with information on company financials and
pipeline products, wherever available.

Scope

- Market size and company share data for In Vitro Diagnostics market categories – Clinical
Chemistry, Haematology, Immuno Chemistry, Histology And Cytology, Infectious Immunology,
Microbiology Culture and Genetic Testing.
- Annualized market revenues (USD million) data for each of the segments and sub-segments
within market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the market categories.
- Global corporate-level profiles of key companies operating within the New Zealand In Vitro
Diagnostics market.
- Key players covered include Sysmex Corporation, F. Hoffmann-La Roche Ltd., Abbott
Laboratories, Beckman Coulter, Inc., Siemens Healthcare, Becton, Dickinson and Company and
others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for
strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the New Zealand In Vitro
Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to
register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product
distribution – Identify, understand and capitalize.
Buy a copy of this report @ http://www.reportsnreports.com/reports/215452-
new-zealand-in-vitro-diagnostics-market-outlook-to-2018-clinical-chemistry-
genetic-testing-haematology-histology-and-cytology-immuno-chemistry-
infectious-immunology-and-microbiology-culture.html

Report Details:

Published: January 2013
No. of Pages: 263

Price: Single User License: US$2500               Corporate User License: US$7500




Points from Table of Contents :
1.1 List of Tables 9
1.2 List of Figures 13
2 Introduction 16
2.1 What is This Report About? 16
3 In Vitro Diagnostics In New Zealand 17
3.1 In Vitro Diagnostics, Market Segmentation 17
3.2 In Vitro Diagnostics, New Zealand, Overall Revenue ($m), USD Constant, 2004-2018 18
3.3 In Vitro Diagnostics Market, New Zealand, Revenue Mix ($m), 2011 20
3.4 In Vitro Diagnostics Market, New Zealand, Category Contribution (%), 2011 21
3.5 In Vitro Diagnostics, New Zealand, Company Share (2010-2011) 28
4 Clinical Chemistry In New Zealand 30
4.1 Clinical Chemistry, Market Segmentation 30
4.2 Clinical Chemistry Market, New Zealand, Revenue Mix ($m), 2011 31
4.3 Clinical Chemistry Market, New Zealand, Segment Contribution (%), 2011 32
4.4 Clinical Chemistry Overall Revenue, (2004-2018) 33
4.4.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 37
4.4.2 Urine Analysis, Revenue (2004-2018) 41
4.5 Clinical Chemistry Distribution Share (2010-2011) 45
4.6 Clinical Chemistry, New Zealand, Company Share (2010-2011) 46
5 Genetic Testing In New Zealand 48
5.1 Genetic Testing, Market Segmentation 48
5.2 Genetic Testing Market, New Zealand, Revenue Mix ($m), 2011 49
5.3 Genetic Testing Market, New Zealand, Segment Contribution (%), 2011 50
5.4 Genetic Testing Overall Revenue, (2004-2018) 51
5.5 Genetic Testing Distribution Share (2010-2011) 55
5.6 Genetic Testing, New Zealand, Company Share (2010-2011) 56
6 Haematology In New Zealand 58
6.1 Haematology Market, Market Segmentation 58
6.2 Haematology Market, New Zealand, Revenue Mix ($m), 2011 59
6.3 Haematology Market, New Zealand, Segment Contribution (%), 2011 60
6.4 Haematology Overall Revenue, (2004-2018) 61
6.4.1 Haematology Reagents, Revenue (2004-2018) 65
6.4.2 Immunohaematology, Revenue (2004-2018) 69
6.4.3 Haemostasis, Revenue (2004-2018) 73
6.4.4 Haematology Rapid Tests, Revenue (2004-2018) 77
6.4.5 Haematology Cell Counters, Revenue (2004-2018) 81
6.5 Haematology Distribution Share (2010-2011) 85
6.6 Haematology, New Zealand, Company Share (2010-2011) 86
7 Histology And Cytology In New Zealand 88
7.1 Histology And Cytology Market, Market Segmentation 88
7.2 Histology And Cytology Market, New Zealand, Revenue Mix ($m), 2011 89
7.3 Histology And Cytology Market, New Zealand, Segment Contribution (%), 2011 90
7.4 Histology And Cytology Overall Revenue, (2004-2018) 91
7.5 Histology And Cytology Distribution Share (2010-2011) 95
7.6 Histology And Cytology, New Zealand, Company Share (2010-2011) 96
8 Immuno Chemistry In New Zealand 98
8.1 Immuno Chemistry Market, New Zealand, Revenue Mix ($m), 2011 98
8.2 Immuno Chemistry Market, New Zealand, Segment Contribution (%), 2011 99
8.3 Immuno Chemistry Overall Revenue, (2004-2018) 100
8.3.1 Disease Specific Immunochemistry, Revenue, (2004-2018) 104
8.3.2 Drugs of Abuse / Toxicology, Revenue, (2004-2018) 108
8.3.3 Endocrinology Tests, Revenue, (2004-2018) 112
8.3.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 116
8.3.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 120
8.3.6 Immunochemistry Analyzers, Revenue (2004-2018) 124
8.4 Immuno Chemistry Distribution Share (2010-2011) 128
8.5 Immuno Chemistry, New Zealand, Company Share (2010-2011) 129
9 Infectious Immunology In New Zealand 131
9.1 Infectious Immunology, Market Segmentation 131
9.2 Infectious Immunology Market, New Zealand, Revenue Mix ($m), 2011 132
9.3 Infectious Immunology Market, New Zealand, Segment Contribution (%), 2011 133
9.4 Infectious Immunology Overall Revenue, (2004-2018) 134
9.4.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 138
9.5 Infectious Immunology Distribution Share (2010-2011) 142
9.6 Infectious Immunology, New Zealand, Company Share (2010-2011) 143
10 Microbiology Culture In New Zealand 145
10.1 Microbiology Culture, Market Segmentation 145
10.2 Microbiology Culture Market, New Zealand, Revenue Mix ($m), 2011 146
10.3 Microbiology Culture Market, New Zealand, Segment Contribution (%), 2011 147
10.4 Microbiology Culture Overall Revenue, (2004-2018) 148
10.4.1 Microbiology Analyzers, Revenue (2004-2018) 152
10.5 Microbiology Culture Distribution Share (2010-2011) 156
10.6 Microbiology Culture, New Zealand, Company Share (2010-2011) 157
11 Overview of Key Companies in New Zealand In Vitro Diagnostics Market 159
11.1 Sysmex Corporation 159
11.1.1 Company Overview 159
11.1.2 Share in the New Zealand In Vitro Diagnostics Market 159
11.2 F. Hoffmann-La Roche Ltd. 160
11.2.1 Company Overview 160
11.2.2 Share in the New Zealand In Vitro Diagnostics Market 160
11.3 Abbott Laboratories 161
11.3.1 Company Overview 161
11.3.2 Share in the New Zealand In Vitro Diagnostics Market 161
11.4 Beckman Coulter, Inc. 162
11.4.1 Company Overview 162
11.4.2 Share in the New Zealand In Vitro Diagnostics Market 162
11.5 Siemens Healthcare 163
11.5.1 Company Overview 163
11.5.2 Share in the New Zealand In Vitro Diagnostics Market 163
11.6 Becton, Dickinson and Company 164
11.6.1 Company Overview 164
11.6.2 Share in the New Zealand In Vitro Diagnostics Market 164
11.7 Ortho-Clinical Diagnostics Inc. 165
11.7.1 Company Overview 165
11.8 bioMerieux S.A. 165
11.8.1 Company Overview 165
11.9 Bio-Rad Laboratories, Inc. 166
11.9.1 Company Overview 166
11.10 Alere Inc. 166
11.10.1 Company Overview 166
11.11 Qiagen N.V. 167
11.11.1 Company Overview 167
11.12 Life Technologies Corporation 167
11.12.1 Company Overview 167
11.13 DiaSorin S.p.A 168
11.13.1 Company Overview 168
11.14 Horiba, Ltd. 168
11.14.1 Company Overview 168
11.15 Danaher Corporation 169
11.15.1 Company Overview 169
11.16 Mindray Medical International Limited 169
11.16.1 Company Overview 169
11.17 Grifols, S.A. 170
11.17.1 Company Overview 170
11.18 PerkinElmer, Inc. 170
11.18.1 Company Overview 170
11.19 Thermo Fisher Scientific Inc. 171
11.19.1 Company Overview 171
11.20 Gen-Probe Incorporated 171
11.20.1 Company Overview 171
11.21 Diagnostica Stago, Inc. 172
11.21.1 Company Overview 172
11.22 Phadia AB 172
11.22.1 Company Overview 172
12 In Vitro Diagnostics Market Pipeline Products 173
12.1 Clinical Chemisty Market Pipeline Products 173
12.2 Immuno Chemistry Market Pipeline Products 176
12.3 Haematology Market Pipeline Products 187
12.4 Infectious Immunology Market Pipeline Products 189
12.5 Microbiology Culture Market Pipeline Products 196
12.6 Histology And Cytology Market Pipeline Products 197
12.7 Genetic Testing Market Pipeline Products 198
13 Financial Deals Landscape 203
13.1 Partnerships 203
13.1.1 Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs For
Transcreener Epigen Methyltransferase Assay 203
13.1.2 bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 205
13.1.3 Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For
Archimedes Particle Metrology System 207
13.1.4 Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 208
13.1.5 BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology
Assays 209
13.1.6 CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital
Microscopy Hematology Solutions 210
13.1.7 Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress
Dx Test 212
13.1.8 Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology
214
13.1.9 CML HealthCare Enters Into Agreement With MaRS Innovation 215
13.1.10 Akrivis Technologies Enters Into Co-Development Agreement With United States
Biological 216
13.1.11 Castle Biosciences Enters Into Licensing Agreement With Brigham and Women''s
Hospital For Mesothelioma Test 217
13.1.12 Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein
Array Products 218
13.1.13 GeneCentric Diagnostics Enters Into Licensing Agreement With University of North
Carolina 219
13.1.14 Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium
TB Test 220
13.1.15 SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For
PhenoFluor 221
13.1.16 Sysmex Asia Pacific Enters Into Distribution Agreement With DiaSys Diagnostic Systems
222
13.1.17 Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 223
13.1.18 MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test
224
13.1.19 NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus
226
13.1.20 Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 228
13.1.21 Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POC
Test 230
13.1.22 One Lambda Enters Into Co-Marketing Agreement With CellTrend 231
13.1.23 Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For
ALK Cancer Biomarker 232
13.1.24 Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 233
13.1.25 Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG
Marker 234
13.1.26 Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor
Cell Technology 235
13.1.27 Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 236
13.1.28 Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange
PCR Kit 237
13.1.29 Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 238
13.1.30 Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For
Pressure Cycling Technology 239
13.1.31 LipoScience Enters Into Licensing Agreement With Cleveland Clinic 241
13.1.32 GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact
Cyclotron And PET Tracer System 242
13.1.33 Sysmex Extends Distribution Agreement With Roche 243
13.1.34 NexDx Enters Into Licensing Agreement With University of California For Epigenetic
Biomarkers 245
13.1.35 Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 246
13.1.36 ZyGEM Enters Into Co-Development Agreement With USAMRIID 247
14 Appendix 248
14.1 Definitions of Markets Covered in the Report 249
14.1.1 In Vitro Diagnostics 249
14.2 Research Methodology 260
14.3 Secondary Research 260
14.4 Primary Research 261
14.5 Models 261
14.8 GlobalData Consulting 262
14.9 Currency Conversion 263
14.10 Contact Us 263
14.11 Disclaimer 263

Contact sales@reportsandreports.com for more details.